CLINICAL_TRIALS
trial_result
· 2015-10-12
Clinical Trial Update: Proof-of-Concept Study With BMS-817399 to Treat Moderate to Severe Rheumatoid Arthritis [Phase 2]
Summary
Phase 2 proof-of-concept trial evaluating BMS-817399 for moderate to severe rheumatoid arthritis. The study has completed.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: Bristol-Myers Squibb | Conditions: Rheumatoid Arthritis | Phase 2 | Status: COMPLETED